as-miR-937-expressing mesenchymal stem cells

as-miR-937-expressing mesenchymal stem cells is a preclinical, research-stage gene-modified cell therapy consisting of bone marrow-derived mesenchymal stem cells (MSCs) engineered via adeno-associated virus (AAV)-mediated transduction to overexpress the antisense of microRNA-937 (as-miR-937). This modification is designed to inhibit endogenous miR-937, which naturally suppresses the translation of the neuronal transcription factor Brn-4 (POU3F4). By downregulating miR-937, the therapy upregulates Brn-4 protein levels, promoting neuronal development and neuroprotection. In murine models of Alzheimer's disease, transplantation of these modified MSCs has demonstrated the ability to reduce amyloid-beta (Aβ) plaque deposition, increase brain-derived neurotrophic factor (BDNF) levels, and improve cognitive and behavioral performance. The therapy was described in a 2015 study by academic researchers and is not currently associated with a commercial developer.

Other names

as-miR-937 MSCsas-miR937 MSCsas-miR 937 MSCsantisense-miR-937-expressing mesenchymal stem cellsantisense-miR937-expressing mesenchymal stem cellsantisense-miR 937-expressing mesenchymal stem cellsmiR-937-modified MSCsmiR937-modified MSCsmiR 937-modified MSCs